Europe news from FierceBiotech
NewsPharma finds promise, peril in biotech revolution
The problem with the European pharmaceuticals industry--at least in part--is Read more...
SPOTLIGHT: Big Pharma changes rules in emerging markets
Emerging markets are getting more and more attention these days, as drugmakers wake up to the fact that Read more...
European investors sour on biotech market
There's a loud drumbeat of warnings coming from Europe over the sour state of biotech investing. Zhining Xu, an analyst at Seymour Pierce, tells the Financial Times that 2007 was a "Read more...
Astellas faces new delay for Advagraf approval
Japan's Astellas Pharma has run into a new roadblock in its pursuit of regulatory approval of Advagraf, its second generation version of the blockbuster transplant drug Prograf. The FDA has raised Read more...
UCB CEO plots strategy following Cimzia approval
Fresh off the FDA's approval of Cimzia for Crohn's disease, UCB chief executive Roch Doliveux forecast a swift regulatory success in Europe. Cimzia is one of the most closely watched late-stage Read more...
Introgen gets positive Phase III Advexin data
Introgen Therapeutics announced that a preliminary analysis of a late-stage trial of Advexin confirmed their mid-stage efficacy data for patients with recurrent head and neck cancer. And researchers Read more...
Biopharma execs sign on to tout UK's R&D work
A high-profile crew of biopharma execs are signing on to help promote the life sciences industry in the UK. Chris Brinsmead, president of AstraZeneca U.K., will chair a 12-man strategy group for UK Read more...
BioCon buys stake in German pharma company
Fulfilling an earlier promise to acquire a company, Bangalor-based BioCon has spent €30 million to Read more...
Penwest shares dive as pain drug flunks endpoint
Penwest Pharmaceuticals says that a Phase IIa for nalbuphine ER, an extended release pain drug, failed to hit a primary goal. But researchers say that the drug performed well enough on its secondary Read more...
Biocon CEO plans acquisition, spin-off
Biocon chief Kiran Mazumdar-Shaw says the Indian drug developer is close to completing a multimillion-dollar acquisition to push its products in North American and Europe and plans to spin off its Read more...
| Press ReleasesPRESS RELEASe: TRIPS: MEPs give their assent to the modification of the agreement TRIPS: MEPs give their assent to the modification of the agreement External/international trade The European Parliament has given its assent to the modification of the agreement on intellectual Read more... |
Get more Europe coverage at:
Paid Research Reports
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
- The Emerging Role of Postmarketing Clinical Research: Regulatory issues, strategic drivers and overall trends